Replimune’s RP1+nivolumab melanoma BLA faces an FDA decision by Apr 10, 2026. The current cash runway extends to Q1'27. See ...
Replimune Group, Inc. REPL announced positive top-line results from the primary analysis of the IGNYTE study on lead pipeline candidate RP1, in combination with Bristol Myers’ BMY blockbuster ...
On Monday, Replimune Group Inc. (NASDAQ:REPL) is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage. Shares fell sharply ...
Zacks Investment Research on MSN
Wall Street analysts predict a 65.72% upside in Replimune Group (REPL): Here's what you should know
Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, ...
The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $12.82 / share. This is an increase of 10.52% from the prior estimate of $11.60 dated November 14, 2025. The ...
Replimune Group (REPL) has drawn attention after presenting updated clinical data from its IGNYTE phase 2 trial at the ESMO Congress 2025. The study combined RP1 with nivolumab in patients with acral ...
You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Rosalie Chan Every time Rosalie publishes a story, you’ll get an alert straight to your inbox!
Some results have been hidden because they may be inaccessible to you
Show inaccessible results